Isard Labs
Algorithmic trading research · Investor briefing
Search like a lab.·Reject like a fund.
Confidential — prepared for prospective investors · Not an offer to sell securities
The thesis
The same compute-scaled, empirical method that lets AI labs predict the next token — pointed at the next price move. Hypotheses in, evidence out, at scale.
The heritage that made systematic funds compound: reject almost everything. Only signal that is provably non-random earns capital.
The two meet at one gate — and we don’t sell subscriptions, we plug what survives into capital.
Why systematic
Discretionary trading runs on hardwired human biases — and can never answer the only question that matters: was it skill, or was it luck?
Systematic is the only path that can be measured, repeated, and disproved. You can’t trade on intuition forever.
Why this is hard
The strategy memorised the past. It cannot predict the future.
Tomorrow’s information leaked into yesterday’s decision. Invisible. Fatal.
Test a hundred, report the best. That’s not an edge — it’s a lottery winner.
Test enough combinations and you are guaranteed to find a winner in pure noise.3 The only defence: search millions — then try to kill each one.
1 — Chague, De-Losso & Giovannetti, Day Trading for a Living? (2020). 2 — ESMA review of retail CFD accounts (2018). 3 — Bailey, Borwein, López de Prado & Zhu, The Probability of Backtest Overfitting (2014).The wedge
The market ships autonomous “AI agents” trading capital nobody should have trusted them with. Isard is the deliberate opposite.
The gate
We test the idea hard, across many different market conditions — not just the ones that flatter it.
A separate team tries to tear it apart. If there’s a flaw, their job is to find it first.
Every step is documented and locked. Nothing depends on one person remembering how it worked.
Even a good idea has to meet the market at the right time, not just any time.
Once it’s live, we compare every real trade to what we expected. Surprises get caught fast.
The exact methods stay ours. The discipline of running all five is the product.
What survives
The space of possible strategies runs to the trillions. Five disciplines kill all but a few. What survives has earned the right to manage money.
Depth of research
Most of it was rejected — and that is the point. The archive of what didn’t work is the map of where the edge isn’t.
The moat — our origin
Isard LabsIsard Labs is the spin-off — where research method met market experience. Hard to hire. Harder to replicate.
Who built this
Why now
The Isard — the Pyrenean chamois — is sure-footed where others slip. As capital floods toward unauditable “AI agents,” the durable edge belongs to whoever can search at scale and refuse to fool themselves about what they find.
Search like a lab.·Reject like a fund.·The moment compute makes that decisive is now.
The universe
Today we cover the top-20 crypto assets by market cap. The raise widens the same disciplined search into the world’s most liquid futures and ETFs:
BTC, ETH, SOL, XRP, and the rest of the large-cap set — where the research began.
ES (S&P 500), NQ (Nasdaq-100), RTY (Russell 2000) — the deepest, most-traded equity markets.
CL (crude oil), GC (gold) — classic trend and macro markets.
ZN (10-yr Treasury note), ZB (30-yr Treasury bond) — the core of the interest-rate complex.
6E (euro / USD), 6J (Japanese yen / USD) — the most liquid currency futures.
SPY (S&P 500), QQQ (Nasdaq-100), IWM (Russell 2000), TLT (long Treasuries), GLD (gold), USO (oil) + sector ETFs.
The opportunity
Against this, a US$1B fund is a fraction of a fraction. The ceiling on this business isn’t market capacity — it’s how much validated edge we can manufacture. Compute lifts that ceiling.
1 — SIFMA / Visual Capitalist, global equity market cap (2024). 2 — SIFMA, global bond market (2024). 3 — BIS Triennial Survey, daily FX turnover (Apr 2022). 4 — HFR, hedge-fund industry AUM (2024).The business model
Isard Labs delivers a validated, ready-to-build strategy methodology. A fund — new or existing — builds and operates it. Our service contract: 1% per year on AUM (the capital the fund manages) + 10% of profits. Revenue scales with each client fund:
| AUM per fund | 1 fund | 5 funds | 10 funds |
|---|---|---|---|
| US$100M | US$3M | US$15M | US$30M |
| US$500M | US$15M | US$75M | US$150M |
| US$1B | US$30M | US$150M | US$300M |
Isard Labs annual revenue. We carry no market risk and no fund operations — we are paid to provide the edge.
Illustrative — 1%/yr AUM + 10% of profit, assuming each fund nets ~20%/yr (≈3% of AUM per fund). Fee terms indicative, pending contracts & legal review.The ask
The bottleneck between a validated 10% strategy and a validated 20–30% one is search at scale. This raise turns one machine into a fleet — and runs the candidates through the gate.
Valuation framing
5 years of research fused with two decades of academic + trading-floor experience — est. US$20–40M and years to rebuild.
At ~US$1B of client AUM, our 1%/yr + 10%-profit fees (~US$30M/yr) cover the entire lab — every additional fund is upside, with no market risk to us.
Priced pre-revenue, on team + thesis: Anthropic raised US$124M (Series A, 2021); OpenAI took US$1B from Microsoft (2019) at ~US$20B.1
Indicative structure: US$50M for 10–15% of the technology company → US$350–500M post-money.
1 — Anthropic, “Anthropic raises $124 million” (2021); TechCrunch, “Microsoft invests $1 billion in OpenAI” (2019). · Illustrative & non-binding, pending verification & legal review. Not an offer or solicitation.The close
We’re raising US$50M to turn an award-winning, academically validated architecture into an institutional-scale Alpha Factory. If that’s a thesis you invest behind — let’s talk.
[ Contact: name · email · LinkedIn — to be inserted ]
Important notice
This document is confidential and provided for discussion purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security or financial instrument, nor a prospectus or offering document. All figures — including strategy returns, AUM, breakeven, valuation, and projections — are illustrative, unaudited, and subject to verification, change, and legal review. Research-volume metrics describe development effort, not investment performance. Systematic and quantitative strategies carry risk, including loss of capital; past or simulated performance is not indicative of future results. Any offering of securities would be made only to qualified/eligible investors via definitive documentation and in compliance with applicable law. [ COMPLIANCE: final wording pending securities/legal review — do not distribute until approved. ]